Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Jonathan Rohll's Articles

OBN Appoints New Non-Executive Director to Enhance Board Expertise

Abingdon, UK: OBN the membership organisation supporting the UK’s innovative life sciences companies, announces today the appointment of Bill Fleming to its Board of Directors, effective immediately

Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering

Philadelphia, USA and Oxford, UK:  Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS.

MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

Glasgow, Scotland:  MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that it has raised $1.15 million in a financing round with existing investors.

Heptares to receive US$12 million milestine payment from AstraZeneca

London, UK: AZD4635 (HTL-1071), a novel adenosine A2A receptor antagonist, reverses adenosine-mediated T-cell suppression and enhances anti-tumour immunity.  New preclinical results presented at AACR Annual Meeting

Imanova receives £1m award from the MRC to develop early markers of dementia - the MIND-MAPS study

Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova has been awarded an additional £1m of strategic funding from the MRC for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease - Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease – Mitochondria, Associated Proteins & Synapses) programme. Kevin Cox, Imanova’s CEO, commented: “We are delighted to have been awarded strategic funding for the MIND-MAPS programme. We would like to thank the MRC and Dementias Platform UK (DPUK) for supporting the proposal and look forward to engaging more widely with the DPUK Imaging Network.” MIND-MAPS is a pre-competitive consortium between Imanova, AbbVie, the MRC, the Hamamatsu Photonics PET centre, drawing on the therapy area expertise of the DPUK members. The aim of the prog ...

Minister breaks ground and unveils name for £13 million office & laboratory building at The Oxford Science Park

The minister of state for universities, science, research and innovation, Jo Johnson MP, visited The Oxford Science Park (“the Park”) on Tuesday 4 April 2017 to take part in an official ground-breaking ceremony and reveal the name of the £13 million state of the art new office and laboratory building capable of accommodating 500 people.

Tissue Solutions introduces additions to their extensive range of cellular products

Tissue Solutions introduces additions to their extensive range of cellular products. Available immediately is their portfolio of human iPS-derived cell types which are conveniently already differentiated and ready to use.

Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD

Oxford, UK, 27 March 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces that it will proceed with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial evaluating the utrophin modulator ezutromid, subject to regulatory approval. This follows an interim review of the safety and tolerability data from the ongoing trial by an independent Data Monitoring Committee ('DMC') and its support of Summit's plans to extend the clinical trial.

The UK's 2017 Spring Budget - Potential Impact on the UK Biotech Industry

Oxford, UK - The Spring Budget delivered by the Chancellor on 8 March 2017 continues to hit the headlines.  What is its potential impact on the UK biotech industry?

Important Milestone Achieved by Isansys Aiming to Improve Monitoring and Save Lives

Abingdon, UK - Patient Status Engine and Lifetouch™ ‘smart bandage’ technology has now monitored more than 1,000 patients in a ground-breaking project transforming the way young patients are cared for.  A ground-breaking project at Birmingham Children’s Hospital using wireless technology to predict deterioration in seriously ill children has recruited its 1,000th patient.

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.

Don't forget about the 'wandering kitchens' near No. 99 on Milton Park on Thursday lunchtime!